Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Travis T Sims

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Plos One|November 22, 2024
Correction: Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancerKyoko Yoshida-Court, Tatiana V Karpinets, Aparna Mitra, et al.
Brachytherapy|August 15, 2025
Iterative intraoperative 3T MRI (iMRI)-guided brachytherapy: A prospective study on enhancing implantation precision and dosimetric gains in advanced gynecologic cancersShrikiriti S Rajan, Matthew S Ning, Megan Jacobson, et al.
International Journal of Radiation Oncology, Biology, Physics|January 29, 2020
Microbial Diversity and Composition Is Associated with Patient-Reported Toxicity during Chemoradiation Therapy for Cervical CancerAparna Mitra, Greyson Willis Grossman Biegert, Andrea Y Delgado, et al.
Brachytherapy|December 21, 2023
Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapyGohar S Manzar, Molly B El Alam, Erica J Lynn, et al.
Plos One|March 4, 2021
A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancersMolly B El Alam, Travis T Sims, Ramez Kouzy, et al.
BMC Cancer|September 1, 2022
Metagenomes of rectal swabs in larger, advanced stage cervical cancers have enhanced mucus degrading functionalities and distinct taxonomic structureTatiana V Karpinets, Xiaogang Wu, Travis Solley, et al.
Research Square|June 22, 2026
The Cervical Microbiome in Hispanic Populations in Texas and Puerto Rico with and without Cervical DysplasiaD'Shaunique Walters, Molly B El Alam, Timothy Harris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2026
First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL-2 in Patients with High-Grade Serous Ovarian CarcinomaHelen D Clark, Samira Aghlara-Fotovat, Jake Schladenhauffen, et al.
Medrxiv : the Preprint Server for Health Sciences|November 26, 2025
First-In-Human Trial of Encapsulated Cell-Based Protein Producers for Localized IL-2 in Patients with High-Grade Serous Ovarian CarcinomaHelen D Clark, Samira Aghlara-Fotovat, Jake Schladenhauffen, et al.
Communications Biology|February 23, 2021
Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiationTravis T Sims, Molly B El Alam, Tatiana V Karpinets, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Plos One|November 22, 2024
Correction: Immune environment and antigen specificity of the T cell receptor repertoire of malignant ascites in ovarian cancerKyoko Yoshida-Court, Tatiana V Karpinets, Aparna Mitra, et al.
Brachytherapy|August 15, 2025
Iterative intraoperative 3T MRI (iMRI)-guided brachytherapy: A prospective study on enhancing implantation precision and dosimetric gains in advanced gynecologic cancersShrikiriti S Rajan, Matthew S Ning, Megan Jacobson, et al.
International Journal of Radiation Oncology, Biology, Physics|January 29, 2020
Microbial Diversity and Composition Is Associated with Patient-Reported Toxicity during Chemoradiation Therapy for Cervical CancerAparna Mitra, Greyson Willis Grossman Biegert, Andrea Y Delgado, et al.
Brachytherapy|December 21, 2023
Exploratory analysis of the cervix tumoral HPV antigen-specific T-cell repertoire during chemoradiation and after brachytherapyGohar S Manzar, Molly B El Alam, Erica J Lynn, et al.
Plos One|March 4, 2021
A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancersMolly B El Alam, Travis T Sims, Ramez Kouzy, et al.
BMC Cancer|September 1, 2022
Metagenomes of rectal swabs in larger, advanced stage cervical cancers have enhanced mucus degrading functionalities and distinct taxonomic structureTatiana V Karpinets, Xiaogang Wu, Travis Solley, et al.
Research Square|June 22, 2026
The Cervical Microbiome in Hispanic Populations in Texas and Puerto Rico with and without Cervical DysplasiaD'Shaunique Walters, Molly B El Alam, Timothy Harris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2026
First-In-Human Trial of Encapsulated Cells Constitutively Expressing Localized IL-2 in Patients with High-Grade Serous Ovarian CarcinomaHelen D Clark, Samira Aghlara-Fotovat, Jake Schladenhauffen, et al.
Medrxiv : the Preprint Server for Health Sciences|November 26, 2025
First-In-Human Trial of Encapsulated Cell-Based Protein Producers for Localized IL-2 in Patients with High-Grade Serous Ovarian CarcinomaHelen D Clark, Samira Aghlara-Fotovat, Jake Schladenhauffen, et al.
Communications Biology|February 23, 2021
Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiationTravis T Sims, Molly B El Alam, Tatiana V Karpinets, et al.
Pageof 4